Survival prediction in patients with resectable colorectal liver metastases: Clinical risk scores and tumor response to chemotherapy

被引:16
作者
Xu, Da [1 ]
Liu, Xiao-Feng [2 ]
Yan, Xiao-Luan [1 ]
Wang, Kun [1 ]
Xing, Bao-Cai [1 ]
机构
[1] Peking Univ, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Sch Oncol,Minist Educ,Hepatopancreatobiliary Surg, 52 Fucheng Rd, Beijing 100142, Peoples R China
[2] Peking Univ, Hlth Sci Ctr, Sch Basic Med Res, Dept Cell Biol, Beijing 100191, Peoples R China
关键词
clinical risk score; colorectal liver metastasis; neo-adjuvant chemotherapy; prognostic factor; survival; tumor response; LONG-TERM SURVIVAL; HEPATIC METASTASES; NEOADJUVANT CHEMOTHERAPY; RESCUE SURGERY; CANCER; RESECTION; CETUXIMAB; TRIAL; KRAS; MANAGEMENT;
D O I
10.3892/ol.2017.7191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical risk scores and response to pre-operative chemotherapy are prognostic factors of colorectal liver metastases. The aim of the present study was to evaluate the effectiveness of combining these factors to predict patient survival and to select patients for curative therapy. The study included 189 patients who underwent hepatectomy following neo-adjuvant chemotherapy, for initially resectable colorectal liver metastases, between January 2005 and December 2015. Patients were stratified into four sub-groups: A1-2, low clinical risk scores with/without a response to pre-operative chemotherapy; and B1-2, high clinical risk scores with or without a response to pre-operative chemotherapy. Treatment and survival data were analysed. Survival was significantly longer in patients with low clinical risk scores and a response to pre-operative chemotherapy; these factors were confirmed as independent prognostic factors by multivariate analysis. Combining clinical risk score and chemotherapy response classification, patient survival was significantly longer for groups A1-2/B1 compared with for group B2, in which only 10.2% of patients were alive after 5 years. Of those with no response to first-line chemotherapy, survival was significantly longer in patients who responded to second-line chemotherapy. A combined clinical risk score and chemotherapy response classification may aid in identifying suitable candidates for potentially curative therapy.
引用
收藏
页码:8051 / 8059
页数:9
相关论文
共 50 条
  • [21] Is There a Survival Benefit to Neoadjuvant Versus Adjuvant Chemotherapy, Combined with Surgery for Resectable Colorectal Liver Metastases?
    Lubezky, Nir
    Geva, Ravit
    Shmueli, Einat
    Nakache, Richard
    Klausner, Joseph M.
    Figer, Arie
    Ben-Haim, Menahem
    WORLD JOURNAL OF SURGERY, 2009, 33 (05) : 1028 - 1034
  • [22] Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases
    Khoo, Emily
    O'Neill, Stephen
    Brown, Ewan
    Wigmore, Stephen J.
    Harrison, Ewen M.
    HPB, 2016, 18 (06) : 485 - 493
  • [23] Is preoperative systemic chemotherapy recommended for resectable colorectal liver metastases?
    Dede Kristof
    Poti Zsuzsa
    Bursics Attila
    ORVOSI HETILAP, 2018, 159 (21) : 823 - 830
  • [24] Perioperative safety in patients with resectable synchronous colorectal liver metastases
    Lee, Lucas D.
    You, Y. Nancy
    CHINESE CLINICAL ONCOLOGY, 2019, 8
  • [25] Neoadjuvant Chemotherapy followed by Hepatectomy for Primarily Resectable Colorectal Cancer Liver Metastases
    Chiappa, Antonio
    Bertani, Emilio
    Makuuchi, Masatoshi
    Zbar, Andrew P.
    Contino, Gianmarco
    Viale, Giuseppe
    Pruneri, Giancarlo
    Bellomi, Massimo
    Della Vigna, Paolo
    Zampino, Maria Giulia
    Fazio, Nicola
    Travaini, Maria Laura
    Trifiro, Giuseppe
    Corbellini, Carlo
    Andreoni, Bruno
    HEPATO-GASTROENTEROLOGY, 2009, 56 (91-92) : 829 - 834
  • [26] The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator
    Ayez, N.
    van der Stok, E. P.
    Grunhagen, D. J.
    Rothbarth, J.
    van Meerten, E.
    Eggermont, A. M.
    Verhoef, C.
    EJSO, 2015, 41 (07): : 859 - 867
  • [27] Topics related to neoadjuvant chemotherapy for resectable liver metastases from colorectal cancer
    Ke, Shanbao
    Zhan, Shufang
    Zhu, Hongbo
    Yan, Danfang
    JOURNAL OF BUON, 2018, 23 (02): : 296 - 301
  • [28] The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy
    Xu, Da
    Yan, Xiao-Luan
    Liu, Jia-Ming
    Li, Juan
    Xing, Bao-Cai
    JOURNAL OF CANCER, 2020, 11 (21): : 6256 - 6263
  • [29] Pathological response grade of colorectal liver metastases treated with neoadjuvant chemotherapy
    Chan, Gabriel
    Hassanain, Mazen
    Chaudhury, Prosanto
    Vrochides, Dionisios
    Neville, Amy
    Cesari, Matthew
    Kavan, Petr
    Marcus, Victoria
    Metrakos, Peter
    HPB, 2010, 12 (04) : 277 - 284
  • [30] Liver Resection for Colorectal Metastases after Chemotherapy Impact of Chemotherapy-Related Liver Injuries, Pathological Tumor Response, and Micrometastases on Long-term Survival
    Vigano, Luca
    Capussotti, Lorenzo
    De Rosa, Giovanni
    De Saussure, Wassila Oulhaci
    Mentha, Gilles
    Rubbia-Brandt, Laura
    ANNALS OF SURGERY, 2013, 258 (05) : 731 - 742